Navigation Links
Enzyme Beneficial to Alzheimer's Plays Darker Role in Other Dementia
Date:4/23/2008

Finding could mean changing animal models used for future research

WEDNESDAY, April 23 (HealthDay News) -- An enzyme shown to help suppress development of Alzheimer's disease appears to hasten progress of a related but far less common type of dementia, according to a new study.

The surprising findings, published in the April 22 online issue of The Journal of Clinical Investigation, are significant, because individuals with frontotemporal dementia with parkinsonism-17 -- a relatively rare hereditary form of dementia -- are often used as models for studying Alzheimer's disease.

Alzheimer's disease and frontotemporal dementia each develop as a result of too many tau proteins accumulating and causing tangled lesions in the brain's neurons. These knotted nerve cells eventually choke off the brain cells responsible for memory.

However, individuals with frontotemporal dementia have mutations in the gene, known as P301L, encoding tau. These mutations have not been found in individuals with Alzheimer's.

Researchers found in mouse models and human cells that boosting levels of the prolyl isomerase (Pin1) enzyme, previously shown to aid in "detangling" tau in Alzheimer's disease, helps break down the tau proteins. However, the same experiments on mice with the genetic mutations in the tau that cause frontotemporal dementia resulted in increased and accelerated tau protein tangling.

"First, we have established a proof of concept that boosting Pin1 activity may offer a new idea for preventing or even treating the tau pathology and neurodegeneration in Alzheimer's disease," senior author Kun Ping Lu, a scientist in the Division of Hematology/Oncology at Beth Israel Deaconess Medical Center, said in a prepared statement. "And, second, given that no tau mutation is found in Alzheimer's patients, this research suggests that it would be prudent to not use P301L tau as an Alzheimer's disease model, especially when screening and testing drugs, as it may produce diametrically opposite effects."

More information

The Alzheimer's Association has more about current treatments for Alzheimer's.



-- Kevin McKeever



SOURCE: Beth Israel Deaconess Medical Center, news release, April 22, 2008


'/>"/>
Copyright©2008 ScoutNews,LLC.
All rights reserved

Related medicine news :

1. Blood pressure enzyme can have tumor-sensing role
2. Enzyme complex could be key to new cancer treatments
3. Elevated liver enzymes associated with higher future mortality
4. Enzyme structure reveals new drug targets for cancer and other diseases
5. Genzyme Delivers Strong Fourth Quarter to Conclude Outstanding Year
6. AGI Dermatics Data Indicates 8 Oxo-Guanine Repair Enzyme OGG1 Encapsulated in Liposomes, Reduces MMP-1, Increases Collagen and Enhances DNA Repair
7. First look at an enzyme target for antibacterial and cancer drugs
8. Caught in the act: The dynamic dance of enzymes
9. McGill researchers link enzyme to breast cancer malignancy
10. Telomerase enzyme structure provides significant new target for anti-cancer therapies
11. Genzyme Receives FDA Response Letter on Synvisc-One(TM)
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:3/29/2017)... ... March 29, 2017 , ... ARI Network Services, Inc. (NASDAQ: ARIS) announced today ... websites for its network of more than 650 U.S.-based dealers. Rhino, a member of ... rotary and flail mowers and cutters, rear blades, post hole diggers, pasture renovators, tillers, ...
(Date:3/29/2017)... , ... March 30, 2017 , ... CHARM CITY RUN ... Run has announced that Mercy Medical Center will serve as the official title sponsor ... region. On Sunday, June 25, 2017, thousands of women will walk or run the ...
(Date:3/29/2017)... ... March 29, 2017 , ... AngioGenesis Labs sold 300 bottles ... AngioGenesis Labs, makers of HeartBoost, BrainBest and BeautyBest, achieved these results while doing ... an over the counter heart healthy drink, can reduce Arterial Plaque, Lower Blood ...
(Date:3/29/2017)... ... March 29, 2017 , ... ... as it continues developing an ANSI-approved, consensus-based American National Standard for Good ... to publish the first ANSI-approved GMP standard for dietary supplements this spring, ...
(Date:3/29/2017)... ... March 29, 2017 , ... HealthCareMandA.com will host an important ... 2017, at 1:00 PM ET. A recording of the webinar will also be made ... , Home health and hospice companies are still popular targets for healthcare investors. This ...
Breaking Medicine News(10 mins):
(Date:3/29/2017)... 29, 2017   Dynatronics Corporation (NASDAQ: ... of Cynthia L. McHenry (Cyndi) as ... for leading Dynatronics manufacturing, distribution, and purchasing operations ... Dynatronics, CEO Kelvyn H. Cullimore, Jr. ... search process conducted by the company as it ...
(Date:3/29/2017)... 29, 2017 On March 28, the U.S. Food and ... with relapsing forms of multiple sclerosis (MS) and primary ... approved by the FDA for PPMS. Ocrevus is an ... "Multiple sclerosis can have a profound impact ... M.D., director of the Division of Neurology Products in ...
(Date:3/29/2017)... , March 29, 2017 /PRNewswire/ - Medicure Inc. ... release financial results for the year ended December ... 26, 2017. The results are being released later ... financial statements will include the operations and balances ... 1, 2016.  This release and filing date meets ...
Breaking Medicine Technology: